{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:51:21Z","timestamp":1791183081695,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e0 degli Studi G. D'Annunzio Chieti Pescara"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Gliomas are aggressive brain tumors with limited treatment options, often leading to poor patient outcomes despite surgery, radiation, and chemotherapy. Current therapies, such as temozolomide and radiation, provide only temporary control, as gliomas frequently develop resistance. Therefore, there is an urgent need for new therapeutics to improve survival and quality of life for patients. In the present study, we explore the hypothesis that the dual inhibition of both the neuronal and inducible nitric oxide synthases could represent a promising therapeutic approach, being these two enzymes often dysregulated in gliomas. To this end, the new quinoline-based compound\n                    <jats:bold>3<\/jats:bold>\n                    was synthetized by a simple, innovative and solvent-free procedure. The molecule was a potent dual inhibitor and demonstrated significant antitumor activity against glioma, both as a monotherapy and in combination with temozolomide.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>\n                    The new quinoline-based compound\n                    <jats:bold>3<\/jats:bold>\n                    was synthetized by a simple, innovative and solvent-free procedure. The molecule was a potent dual nitric oxide synthase inhibitor and demonstrated significant antitumor activity against glioma, both as a monotherapy and in combination with temozolomide.\n                  <\/jats:p>","DOI":"10.1007\/s11030-025-11309-0","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T17:57:34Z","timestamp":1754416654000},"page":"6977-6984","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Discovery of N-[2-(4-methylquinolin-2-yl)phenyl]acetamidine as a new potent nitric oxide synthase inhibitor against glioma progression"],"prefix":"10.1007","volume":"30","author":[{"given":"Marialucia","family":"Gallorini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Amoroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Cataldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Maccallini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"11309_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab200","author":"QT Ostrom","year":"2021","unstructured":"Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2021) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014\u20132018. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noab200","journal-title":"Neuro Oncol"},{"key":"11309_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-024-00516-y","volume":"10","author":"M Weller","year":"2024","unstructured":"Weller M, Wen PY, Chang SM, Dirven L, Lim M, Monje M, Reifenberger G (2024) Glioma. Nat Rev Dis Primers 10:33. https:\/\/doi.org\/10.1038\/s41572-024-00516-y","journal-title":"Nat Rev Dis Primers"},{"key":"11309_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.580101","volume":"7","author":"C Yang","year":"2020","unstructured":"Yang C, Wen HB, Zhao YH, Huang WH, Wang ZF, Li ZQ (2020) Systemic inflammatory indicators as prognosticators in glioblastoma patients: a comprehensive meta-analysis. Front Neurol 7:580101. https:\/\/doi.org\/10.3389\/fneur.2020.580101","journal-title":"Front Neurol"},{"key":"11309_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.14791\/btrt.2024.0035","volume":"12","author":"J Park","year":"2024","unstructured":"Park J, Kim D, Sim J, Kim YJ, Cho K, Moon JH, Sung KS, Yoo J, Lim J (2024) The inflammatory characteristics of symptomatic glioma associated with poor prognosis and chemoresistance via tumor necrosis factor signaling pathway. Brain Tumor Res Treat 12:237\u2013244. https:\/\/doi.org\/10.14791\/btrt.2024.0035","journal-title":"Brain Tumor Res Treat"},{"key":"11309_CR5","doi-asserted-by":"publisher","first-page":"428","DOI":"10.2174\/138161210790232158","volume":"16","author":"W Badn","year":"2010","unstructured":"Badn W, Siesj\u00f6 P (2010) The dual role of nitric oxide in glioma. Curr Pharm Des 16:428\u2013430. https:\/\/doi.org\/10.2174\/138161210790232158","journal-title":"Curr Pharm Des"},{"key":"11309_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216931","volume":"592","author":"T Chen","year":"2024","unstructured":"Chen T (2024) Unveiling the significance of inducible nitric oxide synthase: Its impact on cancer progression and clinical implications. Cancer Lett 592:216931. https:\/\/doi.org\/10.1016\/j.canlet.2024.216931","journal-title":"Cancer Lett"},{"key":"11309_CR7","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1089\/ars.2018.7527","volume":"30","author":"V Somasundaram","year":"2019","unstructured":"Somasundaram V, Basudhar D, Bharadwaj G, No JH, Ridnour LA, Cheng RYS, Fujita M, Thomas DD, Anderson SK, McVicar DW, Wink DA (2019) Molecular mechanisms of nitric oxide in cancer progression, signal transduction, and metabolism. Antioxid Redox Signal 30:1124\u20131143. https:\/\/doi.org\/10.1089\/ars.2018.7527","journal-title":"Antioxid Redox Signal"},{"key":"11309_CR8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/cmdc.201900580","volume":"15","author":"C Maccallini","year":"2020","unstructured":"Maccallini C, Gallorini M, Cataldi A, Amoroso R (2020) Targeting iNOS as a valuable strategy for the therapy of glioma. ChemMedChem 15:339\u2013344. https:\/\/doi.org\/10.1002\/cmdc.201900580","journal-title":"ChemMedChem"},{"key":"11309_CR9","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1096\/fasebj.12.10.773","volume":"12","author":"U F\u00f6rstermann","year":"1998","unstructured":"F\u00f6rstermann U, Boissel JP, Kleinert H (1998) Expressional control of the \u201cconstitutive\u201d isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J 12:773\u2013790","journal-title":"FASEB J"},{"key":"11309_CR10","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1179\/174313208X319099","volume":"30","author":"N Tanriover","year":"2008","unstructured":"Tanriover N, Ulu MO, Isler C, Durak H, Oz B, Uzan M, Akar Z (2008) Neuronal nitric oxide synthase expression in glial tumors: correlation with malignancy and tumor proliferation. Neurol Res 30:940\u2013944. https:\/\/doi.org\/10.1179\/174313208X319099","journal-title":"Neurol Res"},{"key":"11309_CR11","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s12031-023-02166-3","volume":"73","author":"D Kruglyakov","year":"2023","unstructured":"Kruglyakov D, Ojha SK, Kartawy M, Tripathi MK, Hamoudi W, Bazbaz W, Khaliulin I, Amal H (2023) Nitric oxide synthase inhibition prevents cell proliferation in glioblastoma. J Mol Neurosci 73:875\u2013883. https:\/\/doi.org\/10.1007\/s12031-023-02166-3","journal-title":"J Mol Neurosci"},{"key":"11309_CR12","doi-asserted-by":"publisher","first-page":"7739","DOI":"10.1021\/jm100828n","volume":"53","author":"JE Payne","year":"2010","unstructured":"Payne JE, Bonnefous C, Symons KT, Nguyen PM, Sablad M, Rozenkrants N, Zhang Y, Wang L, Yazdani N, Shiau AK, Noble SA, Rix P, Rao TS, Hassig CA, Smith ND (2010) Discovery of dual inducible\/neuronal nitric oxide synthase (iNOS\/nNOS) inhibitor development candidate 4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one (KD7332) part 2: identification of a novel, potent, and selective series of benzimidazole-quinolinone iNOS\/nNOS dimerization inhibitors that are orally active in pain models. J Med Chem 53:7739\u20137755. https:\/\/doi.org\/10.1021\/jm100828n","journal-title":"J Med Chem"},{"key":"11309_CR13","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1124\/jpet.110.172817","volume":"336","author":"KT Symons","year":"2011","unstructured":"Symons KT, Nguyen PM, Massari ME, Anzola JV, Staszewski LM, Wang L, Yazdani N, Dorow S, Muhammad J, Sablad M, Rozenkrants N, Bonefous C, Payne JE, Rix PJ, Shiau AK, Noble SA, Smith ND, Hassig CA, Zhang Y, Rao TS (2011) Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases. J Pharmacol Exp Ther 336:468\u2013478. https:\/\/doi.org\/10.1124\/jpet.110.172817","journal-title":"J Pharmacol Exp Ther"},{"key":"11309_CR14","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1021\/acs.jmedchem.9b01573","volume":"63","author":"MA Cinelli","year":"2020","unstructured":"Cinelli MA, Reidl CT, Li H, Chreifi G, Poulos TL, Silverman RB (2020) First contact: 7-Phenyl-2-Aminoquinolines, potent and selective neuronal nitric oxide synthase inhibitors that target an isoform-specific aspartate. J Med Chem 63:4528\u20134554. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01573","journal-title":"J Med Chem"},{"key":"11309_CR15","doi-asserted-by":"publisher","first-page":"4419","DOI":"10.3390\/molecules26154419","volume":"26","author":"M Gallorini","year":"2021","unstructured":"Gallorini M, Rapino M, Schweikl H, Cataldi A, Amoroso R, Maccallini C (2021) Selective inhibitors of the inducible nitric oxide synthase as modulators of cell responses in LPS-stimulated human monocytes. Molecules 26:4419. https:\/\/doi.org\/10.3390\/molecules26154419","journal-title":"Molecules"},{"key":"11309_CR16","doi-asserted-by":"publisher","first-page":"8486","DOI":"10.3390\/ijms25158486","volume":"25","author":"C Maccallini","year":"2024","unstructured":"Maccallini C, Budriesi R, De Filippis B, Amoroso R (2024) Advancements in the research of new modulators of nitric oxide synthases activity. Int J Mol Sci 25:8486. https:\/\/doi.org\/10.3390\/ijms25158486","journal-title":"Int J Mol Sci"},{"key":"11309_CR17","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1021\/acsmedchemlett.0c00285","volume":"11","author":"C Maccallini","year":"2020","unstructured":"Maccallini C, Arias F, Gallorini M, Amoia P, Ammazzalorso A, De Filippis B, Fantacuzzi M, Giampietro L, Cataldi A, Camacho ME, Amoroso R (2020) Antiglioma activity of aryl and amido-aryl acetamidine derivatives targeting iNOS: Synthesis and biological evaluation. ACS Med Chem Lett 11:1470\u20131475. https:\/\/doi.org\/10.1021\/acsmedchemlett.0c00285","journal-title":"ACS Med Chem Lett"},{"key":"11309_CR18","unstructured":"https:\/\/www.molecular-modelling.ch\/swiss-drug-design.html"},{"key":"11309_CR19","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1021\/acschemneuro.7b00098","volume":"8","author":"X Zhang","year":"2017","unstructured":"Zhang X, Kumata K, Yamasaki T et al (2017) Synthesis and preliminary studies of a novel negative allosteric modulator, 7-((2,5-Dioxopyrrolidin-1-yl)methyl)-4-(2-fluoro-4-[11C]methoxyphenyl) quinoline-2-carboxamide, for imaging of metabotropic glutamate receptor 2. ACS Chem Neurosci 8:1937\u20131948. https:\/\/doi.org\/10.1021\/acschemneuro.7b00098","journal-title":"ACS Chem Neurosci"},{"key":"11309_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.102429","volume":"298","author":"S Yin","year":"2022","unstructured":"Yin S, Pang A, Liu C, Li Y et al (2022) Peptide OM-LV20 protects astrocytes against oxidative stress via the \u201cPAC1R\/JNK\/TPH1\u201d axis. J Biol Chem 298:102429. https:\/\/doi.org\/10.1016\/j.jbc.2022.102429","journal-title":"J Biol Chem"},{"key":"11309_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2015.00059","volume":"9","author":"MF Mu\u00f1oz","year":"2019","unstructured":"Mu\u00f1oz MF, Puebla M, Figueroa XF (2019) Control of the neurovascular coupling by nitric oxide-dependent regulation of astrocytic Ca(2+) signaling. Front Cell Neurosci 9:592015. https:\/\/doi.org\/10.3389\/fncel.2015.00059","journal-title":"Front Cell Neurosci"},{"key":"11309_CR22","doi-asserted-by":"publisher","first-page":"4952019","DOI":"10.3390\/ijms20030495","volume":"20","author":"M Gallorini","year":"2019","unstructured":"Gallorini M, Maccallini C, Ammazzalorso A, Amoia P, De Filippis B, Fantacuzzi M, Giampietro L, Cataldi A, Amoroso R (2019) The selective acetamidine-based iNOS inhibitor CM544 reduces glioma cell proliferation by enhancing PARP-1 cleavage in vitro. Int J Mol Sci 20:4952019. https:\/\/doi.org\/10.3390\/ijms20030495","journal-title":"Int J Mol Sci"},{"key":"11309_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.20517\/cdr.2020.79","volume":"4","author":"N Singh","year":"2021","unstructured":"Singh N, Miner A, Hennis L, Mittal S (2021) Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. Cancer Drug Resist 4:17\u201343. https:\/\/doi.org\/10.20517\/cdr.2020.79","journal-title":"Cancer Drug Resist"},{"key":"11309_CR24","doi-asserted-by":"publisher","first-page":"4891","DOI":"10.3892\/ol.2018.7917","volume":"15","author":"FFB Resende","year":"2018","unstructured":"Resende FFB, Titze-de-Almeida SS, Titze-de-Almeida R (2018) Function of neuronal nitric oxide synthase enzyme in temozolomide-induced damage of astrocytic tumor cells. Oncol Lett 15:4891\u20134899. https:\/\/doi.org\/10.3892\/ol.2018.7917","journal-title":"Oncol Lett"},{"key":"11309_CR25","doi-asserted-by":"publisher","first-page":"14560","DOI":"10.3390\/ijms232314560","volume":"23","author":"A Cataldi","year":"2022","unstructured":"Cataldi A, Amoroso R, di Giacomo V, Zara S, Maccallini C, Gallorini M (2022) The inhibition of the inducible nitric oxide synthase enhances the DPSC mineralization under LPS-induced inflammation. Int J Mol Sci 23:14560. https:\/\/doi.org\/10.3390\/ijms232314560","journal-title":"Int J Mol Sci"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11309-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-025-11309-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11309-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:02:09Z","timestamp":1791180129000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-025-11309-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["11309"],"URL":"https:\/\/doi.org\/10.1007\/s11030-025-11309-0","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"2 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}